Statins as potential therapeutic agents in multiple sclerosis

Olaf Stüve, Thomas Prod'homme, Sawsan Youssef, Shannon Dunn, Oliver Neuhaus, Martin Weber, Hans Peter Hartung, Lawrence Steinman, Scott S. Zamvil

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

3-Hydroxy-3-methylglutaryl coenzyme A (HMG CoA) reductase inhibitors (ie, statins) are oral cholesterol-lowering drugs. Statins are well tolerated and have an excellent safety record. These agents competitively inhibit HMG CoA reductase, which is the enzyme that catalyzes the conversion of HMG CoA to L-mevalonate. Although L-mevalonate is a key intermediate in cholesterol synthesis, several of its metabolites are involved in post-translational modification of specific proteins involved in cell proliferation and differentiation. Thus, independent of their cholesterol-reducing properties, statins have important pleiotropic biologic effects. Recent reports indicate that statins have anti-inflammatory and neuroprotective properties. Whether statins will be of clinical benefit for patients with multiple sclerosis and other neurodegenerative diseases of the central nervous system will only be known after they are evaluated in prospective randomized clinical trials.

Original languageEnglish (US)
Pages (from-to)237-244
Number of pages8
JournalCurrent Neurology and Neuroscience Reports
Volume4
Issue number3
StatePublished - May 2004

Fingerprint

Hydroxymethylglutaryl-CoA Reductase Inhibitors
Multiple Sclerosis
Mevalonic Acid
Cholesterol
Oxidoreductases
Therapeutics
Post Translational Protein Processing
Neurodegenerative Diseases
Cell Differentiation
Anti-Inflammatory Agents
Central Nervous System
Randomized Controlled Trials
Cell Proliferation
Safety
Enzymes
Pharmaceutical Preparations
3-hydroxy-3-methylglutaryl-coenzyme A

ASJC Scopus subject areas

  • Medicine(all)
  • Neuroscience(all)

Cite this

Stüve, O., Prod'homme, T., Youssef, S., Dunn, S., Neuhaus, O., Weber, M., ... Zamvil, S. S. (2004). Statins as potential therapeutic agents in multiple sclerosis. Current Neurology and Neuroscience Reports, 4(3), 237-244.

Statins as potential therapeutic agents in multiple sclerosis. / Stüve, Olaf; Prod'homme, Thomas; Youssef, Sawsan; Dunn, Shannon; Neuhaus, Oliver; Weber, Martin; Hartung, Hans Peter; Steinman, Lawrence; Zamvil, Scott S.

In: Current Neurology and Neuroscience Reports, Vol. 4, No. 3, 05.2004, p. 237-244.

Research output: Contribution to journalArticle

Stüve, O, Prod'homme, T, Youssef, S, Dunn, S, Neuhaus, O, Weber, M, Hartung, HP, Steinman, L & Zamvil, SS 2004, 'Statins as potential therapeutic agents in multiple sclerosis', Current Neurology and Neuroscience Reports, vol. 4, no. 3, pp. 237-244.
Stüve O, Prod'homme T, Youssef S, Dunn S, Neuhaus O, Weber M et al. Statins as potential therapeutic agents in multiple sclerosis. Current Neurology and Neuroscience Reports. 2004 May;4(3):237-244.
Stüve, Olaf ; Prod'homme, Thomas ; Youssef, Sawsan ; Dunn, Shannon ; Neuhaus, Oliver ; Weber, Martin ; Hartung, Hans Peter ; Steinman, Lawrence ; Zamvil, Scott S. / Statins as potential therapeutic agents in multiple sclerosis. In: Current Neurology and Neuroscience Reports. 2004 ; Vol. 4, No. 3. pp. 237-244.
@article{c115838cac9945c7a1ceb4a5b3e743ba,
title = "Statins as potential therapeutic agents in multiple sclerosis",
abstract = "3-Hydroxy-3-methylglutaryl coenzyme A (HMG CoA) reductase inhibitors (ie, statins) are oral cholesterol-lowering drugs. Statins are well tolerated and have an excellent safety record. These agents competitively inhibit HMG CoA reductase, which is the enzyme that catalyzes the conversion of HMG CoA to L-mevalonate. Although L-mevalonate is a key intermediate in cholesterol synthesis, several of its metabolites are involved in post-translational modification of specific proteins involved in cell proliferation and differentiation. Thus, independent of their cholesterol-reducing properties, statins have important pleiotropic biologic effects. Recent reports indicate that statins have anti-inflammatory and neuroprotective properties. Whether statins will be of clinical benefit for patients with multiple sclerosis and other neurodegenerative diseases of the central nervous system will only be known after they are evaluated in prospective randomized clinical trials.",
author = "Olaf St{\"u}ve and Thomas Prod'homme and Sawsan Youssef and Shannon Dunn and Oliver Neuhaus and Martin Weber and Hartung, {Hans Peter} and Lawrence Steinman and Zamvil, {Scott S.}",
year = "2004",
month = "5",
language = "English (US)",
volume = "4",
pages = "237--244",
journal = "Current Neurology and Neuroscience Reports",
issn = "1528-4042",
publisher = "Current Medicine Group",
number = "3",

}

TY - JOUR

T1 - Statins as potential therapeutic agents in multiple sclerosis

AU - Stüve, Olaf

AU - Prod'homme, Thomas

AU - Youssef, Sawsan

AU - Dunn, Shannon

AU - Neuhaus, Oliver

AU - Weber, Martin

AU - Hartung, Hans Peter

AU - Steinman, Lawrence

AU - Zamvil, Scott S.

PY - 2004/5

Y1 - 2004/5

N2 - 3-Hydroxy-3-methylglutaryl coenzyme A (HMG CoA) reductase inhibitors (ie, statins) are oral cholesterol-lowering drugs. Statins are well tolerated and have an excellent safety record. These agents competitively inhibit HMG CoA reductase, which is the enzyme that catalyzes the conversion of HMG CoA to L-mevalonate. Although L-mevalonate is a key intermediate in cholesterol synthesis, several of its metabolites are involved in post-translational modification of specific proteins involved in cell proliferation and differentiation. Thus, independent of their cholesterol-reducing properties, statins have important pleiotropic biologic effects. Recent reports indicate that statins have anti-inflammatory and neuroprotective properties. Whether statins will be of clinical benefit for patients with multiple sclerosis and other neurodegenerative diseases of the central nervous system will only be known after they are evaluated in prospective randomized clinical trials.

AB - 3-Hydroxy-3-methylglutaryl coenzyme A (HMG CoA) reductase inhibitors (ie, statins) are oral cholesterol-lowering drugs. Statins are well tolerated and have an excellent safety record. These agents competitively inhibit HMG CoA reductase, which is the enzyme that catalyzes the conversion of HMG CoA to L-mevalonate. Although L-mevalonate is a key intermediate in cholesterol synthesis, several of its metabolites are involved in post-translational modification of specific proteins involved in cell proliferation and differentiation. Thus, independent of their cholesterol-reducing properties, statins have important pleiotropic biologic effects. Recent reports indicate that statins have anti-inflammatory and neuroprotective properties. Whether statins will be of clinical benefit for patients with multiple sclerosis and other neurodegenerative diseases of the central nervous system will only be known after they are evaluated in prospective randomized clinical trials.

UR - http://www.scopus.com/inward/record.url?scp=17544389566&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=17544389566&partnerID=8YFLogxK

M3 - Article

VL - 4

SP - 237

EP - 244

JO - Current Neurology and Neuroscience Reports

JF - Current Neurology and Neuroscience Reports

SN - 1528-4042

IS - 3

ER -